SEE THE PERSONAL STORIES OF PEOPLE TREATED WITH SPINRAZA

For the 11,000+ people
who have been treated with
SPINRAZA worldwide,*
victories are personal.

*Based on commercial patients, early access patients, and clinical trial participants through September 2021.

Discover SPINRAZA: the first FDA-approved
treatment for SMA

7+ years

Safety and efficacy
evaluated
in the longest
clinical trial in
SMA to date

3x/year

SPINRAZA is directly delivered to

the central nervous system (CNS)
where
motor neuron loss begins.
After 4
initial loading doses,
SPINRAZA is
given 3 times a year.

From 3 days^† to 80 years old^‡§

There’s someone from almost every
age group who has been treated
with SPINRAZA.

WATCH SOME OF THEIR STORIES

^†Includes clinical trial patients.

^‡Pivotal clinical studies of SPINRAZA included patients from 3 days to 16 years of age at first dose, but did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger patients.

^§Based on commercial patients in the US (including Puerto
Rico) through December 2020.

Demonstrated efficacy in people with early- and later-onset SMA

SEE THE DATA

Safety & side effects

The most common side effects of
SPINRAZA include lower respiratory
infection, fever, constipation, headache,
vomiting, back pain, and post-lumbar
puncture syndrome. These are not all of
the possible side effects of SPINRAZA.

SEE SAFETY PROFILE

How SPINRAZA works

SPINRAZA targets an underlying cause of muscle weakness in SMA.

SEE HOW IT WORKS

For the 11,000+ people
who have been treated with
SPINRAZA worldwide,*
victories are personal.